Aegerion Pharmaceuticals Inc., of Cambridge, Mass., said Health Canada has granted approved Juxtapid (lomitapide) as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without low-density lipoprotein (LDL) apheresis, to reduce LDL-cholesterol in adult patients with homozygous familial hypercholesterolemia.